Forbion’s Post

📢€75m Raised by Merger for Innate Immunity Breakthrough 💰 Dutch biotech firm Forbion has led a €75m Series A financing round for newly formed company Calluna Pharma. Calluna was created through the merger of Oxitope Pharma and Arxx Therapeutics and aims to develop therapies for inflammatory and fibrotic diseases. Its pipeline includes four selective antibodies targeting immunological diseases, with CAL101 being the lead program. The funding will be used to develop Calluna's pipeline to key clinical milestones. #BioprocessUpdates #innateimmunity #merger #biotech #financing #SeriesA #pharmaceuticals #therapy #inflammatorydiseases #fibroticdiseases #antibodies #immunologicaldiseases #clinicalmilestones #Dutchbiotech #OxitopePharma #ArxxTherapeutics ▷ Read the full article here: 📎 https://lnkd.in/dJesXRF6

Boston is considered by many to be the capital of the #biotech world. But who are the top rising biotechs right now? 🔥 Here are the top 6, ranked by amount raised in the last 2 years: 6. Cellarity: October 2022 - series C - $121 million 5. MOMA Therapeutics: May 2022 - series B - $150 million 4. Orna Therapeutics: August 2022 - series B - $221 million 3. Neumora Therapeutics: October 2022 - series B - $112 million + September 2023 - IPO $250 million 2. Tessera Therapeutics: April 2022 - series C - $300 million 1. ElevateBio: May 2023 - series D - $401 million Labiotech.eu has a list including 6 more companies to watch in the Boston area (link in comments). .................................. #boston #drugdevelopment

#fundingalert 💼Company: Enlaza Therapeutics  💰Funding: $100Million ⚡Round: Series A  👥Investors: J.P. Morgan Asset Management, Frazier Life Sciences, Avalon Ventures, Lightspeed, Samsara BioCapital, Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, Stephen Squinto Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The financing will be used to further develop Enlaza’s proprietary covalent protein technologies and to support advancement of wholly owned pipeline programs to the clinic. Sergio Duron, Stephen Squinto, Analeah Heidt, Sateesh Natarajan Read more - https://lnkd.in/d2b2YpS3 To share your startup story write us on - contact@startuprise.io #EnlazaTherapeutics #biologics #proteintechnologies #funding #fundingnews #startupnews #news #startuprise

The Column Group (TCG) unveils its innovative strategy for funding single-asset biologic companies with the launch of TCG Labs and Soleil, a Bay Area R&D hub. With over $400 million raised for this initiative, TCG aims to streamline drug development and address challenges in the biotech industry, such as escalating research costs and talent retention. Led by CEO Jin-Long Chen, Soleil will focus on early-stage research and Phase I or II trials before offering single assets to larger biotech or pharmaceutical firms. This approach aims to maximize returns for founders and investors while maintaining a core team of researchers at Soleil. TCG's model diverges from traditional biotech startup strategies, emphasizing asset sales over company acquisitions. By concentrating solely on single assets, TCG Labs seeks to provide a more efficient and sustainable path to drug development. With experienced leadership, including Lucinda Quan and NGM veterans, TCG Labs sets ambitious goals in disease areas like oncology, autoimmune, and cardiovascular diseases. The firm's track record of successful exits through M&A underscores its commitment to generating value for investors and fostering long-term research initiatives. As TCG Labs-Soleil emerges as a pioneering force in biotech funding, its innovative approach promises to reshape the landscape of drug development and investment strategies in the biopharmaceutical industry. Source: https://lnkd.in/eC4m9eRN

Have you caught up with what's been happening in the #lifescience industry? Here's some of the biggest news we've seen this week: 🎁 PharmiWeb Celebrates its 25th Anniversary (of course we had to be on the list!): https://buff.ly/47AWFgu 💰 Biotech Companies to Increase R&D Spend but Highlight Complexity of Clinical Trials: https://buff.ly/420yVRR 🤝 GSK Enters Agreement to Acquire Aiolos Bio: https://buff.ly/47sR0cw 🔬 Boehringer Ingelheim Enters 2024 on a High Note - Announcing Five New R&D Partnerships: https://buff.ly/3vwHLeb 🤝 Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline: https://buff.ly/3u05Fy1 #news #pharmaceuticals #clinicalresearch #biotechnology

Have you caught up with what's been happening in the #lifescience industry? Here's some of the biggest news we've seen this week: 🎁 PharmiWeb Celebrates its 25th Anniversary (of course we had to be on the list!): https://buff.ly/47AWFgu 💰 Biotech Companies to Increase R&D Spend but Highlight Complexity of Clinical Trials: https://buff.ly/420yVRR 🤝 GSK Enters Agreement to Acquire Aiolos Bio: https://buff.ly/47sR0cw 🔬 Boehringer Ingelheim Enters 2024 on a High Note - Announcing Five New R&D Partnerships: https://buff.ly/3vwHLeb 🤝 Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline: https://buff.ly/3u05Fy1 #news #pharmaceuticals #clinicalresearch #biotechnology

Have you caught up with what's been happening in the #lifescience industry? Here's some of the biggest news we've seen this week: 🎁 PharmiWeb Celebrates its 25th Anniversary (of course we had to be on the list!): https://buff.ly/47AWFgu 💰 Biotech Companies to Increase R&D Spend but Highlight Complexity of Clinical Trials: https://buff.ly/420yVRR 🤝 GSK Enters Agreement to Acquire Aiolos Bio: https://buff.ly/47sR0cw 🔬 Boehringer Ingelheim Enters 2024 on a High Note - Announcing Five New R&D Partnerships: https://buff.ly/3vwHLeb 🤝 Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline: https://buff.ly/3u05Fy1 #news #pharmaceuticals #clinicalresearch #biotechnology

Have you caught up with what's been happening in the #lifescience industry? Here's some of the biggest news we've seen this week: 🎁 PharmiWeb Celebrates its 25th Anniversary (of course we had to be on the list!): https://buff.ly/47AWFgu 💰 Biotech Companies to Increase R&D Spend but Highlight Complexity of Clinical Trials: https://buff.ly/420yVRR 🤝 GSK Enters Agreement to Acquire Aiolos Bio: https://buff.ly/47sR0cw 🔬 Boehringer Ingelheim Enters 2024 on a High Note - Announcing Five New R&D Partnerships: https://buff.ly/3vwHLeb 🤝 Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline: https://buff.ly/3u05Fy1 #news #pharmaceuticals #clinicalresearch #biotechnology

Have you caught up with what's been happening in the #lifescience industry? Here's some of the biggest news we've seen this week: 🎁 PharmiWeb Celebrates its 25th Anniversary (of course we had to be on the list!): https://buff.ly/47AWFgu 💰 Biotech Companies to Increase R&D Spend but Highlight Complexity of Clinical Trials: https://buff.ly/420yVRR 🤝 GSK Enters Agreement to Acquire Aiolos Bio: https://buff.ly/47sR0cw 🔬 Boehringer Ingelheim Enters 2024 on a High Note - Announcing Five New R&D Partnerships: https://buff.ly/3vwHLeb 🤝 Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline: https://buff.ly/3u05Fy1 #news #pharmaceuticals #clinicalresearch #biotechnology

Have you caught up with what's been happening in the #lifescience industry? Here's some of the biggest news we've seen this week: 🎁 PharmiWeb Celebrates its 25th Anniversary (of course we had to be on the list!): https://buff.ly/47AWFgu 💰 Biotech Companies to Increase R&D Spend but Highlight Complexity of Clinical Trials: https://buff.ly/420yVRR 🤝 GSK Enters Agreement to Acquire Aiolos Bio: https://buff.ly/47sR0cw 🔬 Boehringer Ingelheim Enters 2024 on a High Note - Announcing Five New R&D Partnerships: https://buff.ly/3vwHLeb 🤝 Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline: https://buff.ly/3u05Fy1 #news #pharmaceuticals #clinicalresearch #biotechnology